Delve deep into the dynamic landscape of the diagnostic specialty antibodies market with our comprehensive market research report. This sector, heralding an era of precise disease detection and subsequent treatments, is set to experience bounds in growth owing to remarkable advancements in DNA-based technologies and diagnostics.
Capitalizing on an increased prevalence of diseases such as cancer, infectious diseases, and influenza, this market is further propelled by the rising global demand for specialized diagnostics. The study specifically highlights how monoclonal and polyclonal antibodies, specifically, are increasingly used in techniques like immunohistochemistry for the detection of pathogen antigens, making them an invaluable tool in the diagnosis of diseases like HIV and even some forms of cancer.
While the diagnostic antibodies market navigates some challenges such as high development costs, recent product launches and partnerships among major players promise an optimistic future. The report also presents detailed insights on trends such as the growing importance of monoclonal antibodies in diagnosing various diseases. Learn how the market is performing across different regions, with a special focus on North America's significant market share, driven by well-established healthcare infrastructure, high R&D investments, and prevalent cancer cases.
Harness the power of informed decision-making with our detailed analysis of the market competitive landscape, featuring key international and local companies. Discover the technological progressions and innovative endeavors that are shaping the future of diagnostic specialty antibodies market. This report equips you with not just insights but strategies for success.
The COVID-19 pandemic has had a substantial impact on the diagnostic specialty antibodies market. The usage of diagnostic antibodies underwent a significant rise during the pandemic as these antibodies were adopted quickly for the detection of COVID-19 during the pandemic. For instance, according to an article published by PubMed Central in February 2021, the main-stream diagnostic methods used during the pandemic to detect the presence of SARS-CoV-2 virus in the laboratory include nucleic acid PCR tests and direct viral antigen tests for detecting active infections, and indirect human antibody tests specific to SARS-CoV-2 to detect prior exposure. Furthermore, according to FDA in February 2022, SARS-CoV-2 antibody tests can help identify people who may have been infected with the SARS-CoV-2 virus or have recovered from COVID-19. But the antibody tests cannot be used to detect active COVID-19 infection. Currently, the usage of antibodies for COVID-19 testing lowered drastically as other tests like PCR and antigen tests have become much more popular due to the confirmatory results that they provide. Thus, the COVID-19 outbreak affected the market's growth favorably in its preliminary phase; however, during the forecast period, the market is likely to go back to how it was during the pre-pandemic phase.
The advancements in DNA-based technologies and diagnostics are expected to boost market growth. In addition, the high number of patient pools undergoing diagnosis of HIV and the growing demand for specialty diagnostics around the world are projected to fuel the market. Furthermore, the increase in the prevalence of diseases such as infectious diseases, influenza, and cancer is expected to boost the diagnostic antibodies market.
For instance, according to an article published by BMC in January 2022, immunohistochemistry (IHC) using monoclonal and polyclonal antibodies is a very useful and popular diagnostic method for detecting pathogen antigens in fixed tissues, it complements the direct diagnosis of infectious diseases by PCR and culture on fresh tissues. The article also stated that the immunohistochemical technique is a rapid and efficient way of identifying HIV antigens in fixed surgical and autopsy specimens. The immunohistochemistry technique using an anti-p24 monoclonal antibody has proven to be very useful for detecting HIV in lymph node biopsies of patients with unexplained follicular hyperplasia.
In addition, new key developments and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, according to an article published by MDPI in April 2021, monoclonal antibodies are an emerging tool for cancer diagnosis, treatment and even delivering radiation or chemotherapy to targeted areas of the body. Recently, researchers have cloned a new anti-p16 antibody that may become a new valuable tool for pathological cancer diagnosis. Thus, owing to the product launches and partnerships, the studied market is expected to have significant growth over the forecast period.
However, the high cost of the development of antibodies in rapid diagnosis is expected to hamper the market growth.
Diagnostic Specialty Antibodies Market Trends
Monoclonal Antibodies are Expected to have Significant Growth Over the Forecast PeriodMonoclonal antibodies play a vital role in the diagnosis of many infectious and chronic diseases such as cancer. The increase in the number of research activities on monoclonal antibodies and their applications in various disease diagnoses along with a growing number of cancer cases and increasing awareness regarding early diagnosis is expected to boost segment growth.
For instance, according to an article published by the Biomedical Journal of Scientific & Technical Research in September 2020, monoclonal antibodies have prominent applications in diagnosis, so they are incorporated into diagnostic techniques (western immunoblotting, ELISA, immunofluorescence test, and immunohistochemistry) for the diagnosis of various diseases. Monoclonal antibodies in diagnostic tests are important for detecting an antigen or antibody against microbes. Monoclonal antibodies also play a significant role in the development of specific serologic reagents for antigens in limited amounts. They provide both highly specific and reproducible immunological assays for rapid and accurate diagnosis of different types of infectious diseases.
Furthermore, continuous product launches by major players in the market are positively affecting the growth of the segment. For instance, in October 2022, Roche announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma. The PRAME (EPR20330) antibody is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions.
Therefore, the monoclonal antibodies segment is expected to witness significant growth over the forecast period due to the abovementioned factors.
North America is Projected to Have Significant Market Growth Over the Forecast PeriodNorth America is projected to have a significant market share among the regions owing to the adaptation of various antibody diagnostics coupled with well-established healthcare infrastructure in the region. In addition, new product launches, high R&D investments, and the growing number of cancer cases are some of the factors that are fuelling the market growth in this region. Moreover, favorable government policies and increased funding from the government in cancer research are expected to bolster market growth.
The high prevalence of cancer in the United States is one of the major factors for the growth of the market. For instance, according to the data by the American Cancer Society 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States during 2021. Furthermore, according to the same source, an estimated 54,010 new cases of cancer of the oral cavity and pharynx (throat) will be diagnosed in the US and 10,850 people will die from the disease. Incidence rates were found to be more than twice as high in men as in women. Hence, the high prevalence of cancer in the country will lead to the usage of more diagnostic specialty antibodies for the oncology field, thus is is expected to boost the studied market.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.
Diagnostic Specialty Antibodies Market Competitor AnalysisThe diagnostic specialty antibodies market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known The key market players include F. Hoffmann-La Roche AG, Abcam plc, Bio-Rad Laboratories, Inc., Abbott Laboratories, Agilent Technologies, Inc., Creative Diagnostics, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Merck KGA, and Sartorius AG among others.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Growing R&D Expenditure in Biotech and Pharma Companies
4.2.2 Rising Demand For Diagnostic Antibodies in Diagnosis of Diseases
4.3 Market Restraints
4.3.1 High Cost in Dvelepoment of Antibodies
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Monoclonal Antibodies
5.1.2 Polyclonal Antibodies
5.2 By Application
5.2.1 Oncology Diagnosis
5.2.2 Hepatitis Diagnosis
5.2.3 Infectious Disease Diagnosis
5.3 By End-User
5.3.1 Diagnostic Laboratories
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Abcam plc
6.1.3 Abbott Laboratories
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Agilent Technologies, Inc.
6.1.6 Creative Diagnostics
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Becton, Dickinson and Company
6.1.9 Merck KGaA
6.1.10 Sartorius AG
A selection of companies mentioned in this report includes:
- F. Hoffmann-La Roche AG
- Abcam plc
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Creative Diagnostics
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- Merck KGaA
- Sartorius AG